Exact Sciences Corporation (BIT:1EXAS)

Market Cap	7.26B
Revenue (ttm)	2.50B
Net Income (ttm)	-855.95M
Shares Out	n/a
EPS (ttm)	-4.59
PE Ratio	n/a
Forward PE	55.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	n/a
Previous Close	35.96
Day's Range	n/a
52-Week Range	35.96 - 51.23
Beta	n/a
RSI	26.77
Earnings Date	Jul 28, 2025

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri...

• Industry: Commercial Physical and Biological Research
• Founded: 1995
• Employees: 7,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EXAS

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Financial numbers in USD